An ImmunoPEGliposome for Targeted Antimalarial Combination Therapy at the Nanoscale

Bibliographic Details
Title: An ImmunoPEGliposome for Targeted Antimalarial Combination Therapy at the Nanoscale
Authors: Arnau Biosca, Lorin Dirscherl, Ernest Moles, Santiago Imperial, Xavier Fernàndez-Busquets
Source: Pharmaceutics, Vol 11, Iss 7, p 341 (2019)
Publisher Information: MDPI AG, 2019.
Publication Year: 2019
Collection: LCC:Pharmacy and materia medica
Subject Terms: combination therapy, immunoliposomes, malaria, nanomedicine, nanotechnology, Plasmodium, targeted drug delivery, Pharmacy and materia medica, RS1-441
More Details: Combination therapies, where two drugs acting through different mechanisms are administered simultaneously, are one of the most efficient approaches currently used to treat malaria infections. However, the different pharmacokinetic profiles often exhibited by the combined drugs tend to decrease treatment efficacy as the compounds are usually eliminated from the circulation at different rates. To circumvent this obstacle, we have engineered an immunoliposomal nanovector encapsulating hydrophilic and lipophilic compounds in its lumen and lipid bilayer, respectively. The antimalarial domiphen bromide has been encapsulated in the liposome membrane with good efficiency, although its high IC50 of ca. 1 µM for living parasites complicates its use as immunoliposomal therapy due to erythrocyte agglutination. The conjugation of antibodies against glycophorin A targeted the nanocarriers to Plasmodium-infected red blood cells and to gametocytes, the sole malaria parasite stage responsible for the transmission from the human to the mosquito vector. The antimalarials pyronaridine and atovaquone, which block the development of gametocytes, have been co-encapsulated in glycophorin A-targeted immunoliposomes. The co-immunoliposomized drugs have activities significantly higher than their free forms when tested in in vitro Plasmodium falciparum cultures: Pyronaridine and atovaquone concentrations that, when encapsulated in immunoliposomes, resulted in a 50% inhibition of parasite growth had no effect on the viability of the pathogen when used as free drugs.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1999-4923
Relation: https://www.mdpi.com/1999-4923/11/7/341; https://doaj.org/toc/1999-4923
DOI: 10.3390/pharmaceutics11070341
Access URL: https://doaj.org/article/dc87d6d8a9984940bcbc4f815c4efaba
Accession Number: edsdoj.87d6d8a9984940bcbc4f815c4efaba
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:19994923
DOI:10.3390/pharmaceutics11070341
Published in:Pharmaceutics
Language:English